Certara, Inc. (NASDAQ:CERT) Given Average Rating of “Hold” by Brokerages

Certara, Inc. (NASDAQ:CERT) has been given an average rating of “Hold” by the eight ratings firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $15.92.

A number of research analysts recently weighed in on the company. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Robert W. Baird reduced their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP raised its stake in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Geneva Capital Management LLC raised its stake in Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock valued at $64,525,000 after buying an additional 37,392 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares in the last quarter. State Street Corp raised its stake in Certara by 3.4% during the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after buying an additional 122,411 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

Shares of Certara stock opened at $10.66 on Friday. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The stock has a market capitalization of $1.72 billion, a P/E ratio of -53.30, a PEG ratio of 5.70 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s fifty day moving average price is $10.84 and its 200 day moving average price is $12.89.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter last year, the firm earned $0.06 earnings per share. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, research analysts anticipate that Certara will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.